Structure of Hexaminolevulinate HCl
CAS No.: 140898-91-5
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Hexaminolevulinate HCl is a fluorescent agent which has been approved for cystoscopic detection of papillary bladder cancer.
Synonyms: Hexyl 5-aminolevulinate hydrochloride; P-1206; Hexyl 5- aminolevulinate
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 140898-91-5 |
Formula : | C11H22ClNO3 |
M.W : | 251.75 |
SMILES Code : | Cl.CCCCCCOC(=O)CCC(=O)CN |
Synonyms : |
Hexyl 5-aminolevulinate hydrochloride; P-1206; Hexyl 5- aminolevulinate
|
MDL No. : | MFCD03695491 |
InChI Key : | LZYXPFZBAZTOCH-UHFFFAOYSA-N |
Pubchem ID : | 6433082 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H315-H317-H319-H335 |
Precautionary Statements: | P261-P280-P305+P351+P338 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT02800473 | Bladder Cancer | Not Applicable | Completed | - | France ... More >> Institut de Cancerologie de Lorraine Vandoeuvre-les-Nancy, France, 54519 Less << |
NCT02857634 | - | Completed | - | France ... More >> Groupement des Hôpitaux de l'Institut Catholique de Lille Lomme, Nord, France, 59462 Less << | |
NCT03058705 | Bladder Cancer | Not Applicable | Completed | - | United States, New York ... More >> University of Rochester Medical Center Rochester, New York, United States, 14642 Less << |
NCT02149342 | Actinic Keratoses | Phase 1 Phase 2 | Completed | - | Finland ... More >> Päijät-Häme Central Hospital Lahti, Finland, 15850 Less << |
NCT02149342 | - | Completed | - | - | |
NCT03272659 | Colorectal Cancer ... More >> Photodynamic Diagnosis Less << | Phase 2 | Withdrawn(Long process and due... More >> to strict deadline, project was stopped.) Less << | April 1, 2019 | - |
NCT00496171 | - | Terminated | - | Norway ... More >> Riks-Radium University Hospital Oslo, Norway Less << | |
NCT02560584 | Bladder Cancer | Phase 3 | Completed | - | United States, California ... More >> USC Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 United States, Illinois University of Chicago Medical Center Chicago, Illinois, United States, 60637 United States, Iowa University of Iowa Iowa City, Iowa, United States, 52242 United States, Maryland Johns Hopkins University Baltimore, Maryland, United States, 21205 United States, Minnesota University of Minnesota Minneapolis, Minnesota, United States, 55455 United States, New York Montefiore Medical Center Bronx, New York, United States, 10461 NYU Langone Urology Associates New York, New York, United States, 10016 Columbia University Medical Center New York, New York, United States, 10032 United States, North Carolina University of North Carolina, Department of Urology Chapel Hill, North Carolina, United States, 27599 United States, Ohio Ohio State University The James Cancer Hospital Columbus, Ohio, United States, 43210 United States, Oklahoma University of Oklahoma-Stephenson Cancer Center Oklahoma City, Oklahoma, United States, 73104 United States, Pennsylvania Thomas Jefferson University Philadelphia, Pennsylvania, United States, 10197 United States, Tennessee Vanderbilt University Medical Center Nashville, Tennessee, United States, 37232 United States, Texas UT Southwestern Medical Center Dallas, Texas, United States, 75390 MD Anderson Cancer Center Houston, Texas, United States, 77030 Michael E. DeBakey VA Medical Center Houston, Texas, United States, 77030 United States, Wisconsin University of Wisconsin Madison, Wisconsin, United States, 53792 Less << |
NCT02660190 | Bladder Cancer ... More >> Recurrence PDD Less << | Phase 3 | Active, not recruiting | October 2018 | Denmark ... More >> Herlev Hospital Herlev, Denmark Hospitalsenheden Vest Holstebro, Denmark Less << |
NCT01750970 | Bladder Tumor | Not Applicable | Completed | - | France ... More >> Hôpital FOCH Suresnes, France, 92150 Less << |
NCT02560584 | - | Completed | - | - | |
NCT00369018 | Cervical Dysplasia | Phase 1 Phase 2 | Completed | - | Germany ... More >> Medizinische Hochschule Hannover, Department of Obstetrics and Gynecology Hannover, Germany, 30625 Norway Ullevål University Hospital, Department of Obstetrics and Gynecology Oslo, Norway, 0407 Less << |
NCT01256424 | - | Completed | - | - | |
NCT01256424 | Cervical Intraepithelial Neopl... More >>asia Less << | Phase 2 | Completed | - | Germany ... More >> University Hospital Hannover Hannover, Germany Norway Haukeland University Hospital Bergen, Norway, 5021 Less << |
NCT01282515 | Genital Erosive Lichen Planus | Phase 2 Phase 3 | Unknown | - | Norway ... More >> Rikshospitalet, OsloUniversity hospital Oslo, Norway, 0027 Less << |
NCT00708942 | Cervical Intraepithelial Neopl... More >>asia Less << | Phase 2 | Terminated(Slow recruitment, s... More >>tudy stopped with only 13 of 70 patients included in second part of the study) Less << | - | France ... More >> Department of Obstetrics and Gyneacology, Lille University Hospital Lille, France Germany Department of Obstetrics and Gynecology Hannover, Germany Norway Fritzøe klinikk Larvik, Norway Department of Obstetrics and Gynaecology, Ullevål University Hospital Oslo, Norway Medicus Trondheim, Norway Less << |
NCT02660645 | - | Recruiting | December 2020 | United States, California ... More >> USC/Norris Comprehensive Cancer Center Recruiting Los Angeles, California, United States, 90033 Contact: Ileana Aldana 323-865-0702 ileana.aldana@med.usc.edu Principal Investigator: Sia Daneshmand, MD Sub-Investigator: Anne Schuckman, MD Sub-Investigator: Mihir Desai, MD Sub-Investigator: Hooman Djaladat, MD Sub-Investigator: Gerhard Fuchs, MD Sub-Investigator: Virinder Bhardwaj, MD VA Palo Alto Health Care System Recruiting Palo Alto, California, United States, 94304 Contact: Dorothy Trivedi dtrivedi@stanford.edu Principal Investigator: Joseph Liao, MD Sub-Investigator: James Crotty, MD Sub-Investigator: John Leppert, MD Sub-Investigator: John Lavelle, MD University of California, San Francisco Recruiting San Francisco, California, United States, 94143 Contact: Sima Porten, MD, MPH 415-885-3695 Sima.Porten@ucsf.edu Principal Investigator: Sima Porten, MD, MPH United States, Kansas University of Kansas Medical Center Recruiting Kansas City, Kansas, United States, 66160 Contact: Katie Glavin 913-588-8721 kglavin@kumc.edu Principal Investigator: John Taylor, MD, MS Sub-Investigator: Jeffrey Holzbeierlein, MD, FACS Sub-Investigator: Eugene Lee, MD, FACS Sub-Investigator: Hadley Wyre, MD Sub-Investigator: Moben Mirza, MD United States, Maryland Johns Hopkins Medicine Recruiting Baltimore, Maryland, United States, 21224 Contact: Morgan De Carli Mdecarl2@jhmi.edu Principal Investigator: Trinity Bivalacqua, MD, PhD Sub-Investigator: Phillip Pierorazio, MD United States, Minnesota University of Minnesota Recruiting Minneapolis, Minnesota, United States, 55455 Contact: Therese Perrier 612-625-3319 perri084@umn.edu Principal Investigator: Badrinath Konety, MD Sub-Investigator: Weight Chris, MD Sub-Investigator: Laureen Hemsley, MD United States, New York Stony Brook Urology Recruiting Stony Brook, New York, United States, 11794 Contact: Kim Lyktey Kim.Lyktey@stonybrookmedicine.edu Principal Investigator: John Fitzgerald, MD Sub-Investigator: Massimiliano Spaliviero, MD Sub-Investigator: Wayne Waltzer, MD United States, Ohio Cincinnati VA Medical Center Not yet recruiting Cincinnati, Ohio, United States, 45220 Contact: Krishnanath Gaitonde, MD Principal Investigator: Krishnanath Gaitonde, MD Ohio State University Wexner Medical Center Recruiting Columbus, Ohio, United States, 43210 Contact: Kamal Pohar, MD kamal.pohar@osumc.edu Principal Investigator: Kamal Pohar, MD Sub-Investigator: Megan Merrill, DO Sub-Investigator: Ahmad Shabsigh, MD Sub-Investigator: David Sharp, MD United States, South Carolina Carolina Urology Partners Recruiting West Columbia, South Carolina, United States, 29169 Contact: Nicol Brandon 704-414-2870 ext 2809 Nicol.brandon@carolinaurologypartners.com Principal Investigator: T. Brian Willard, MD Sub-Investigator: David Lamb, MD Sub-Investigator: Scott Sweazy, MD Sub-Investigator: Keith Birghtbill, MD Sub-Investigator: Michael Stotzer, MD United States, Texas UT Southwestern Not yet recruiting Dallas, Texas, United States, 75390 Contact: Yair Lotan, MD 214-645-8787 Principal Investigator: Yair Lotan, MD Sub-Investigator: Aditya Bagrodia, MD Sub-Investigator: Vitaly Margulis, MD Sub-Investigator: Ganesh Raj, MD, PhD Michael E. DeBakey VA Medical Center Recruiting Houston, Texas, United States, 77030 Contact: Ashley Jones, BS, CCRP 713-791-1414 ext 26694 Ashley.Jones2@bcm.edu Principal Investigator: Jennifer Taylor, MD, MPH Sub-Investigator: Jeffrey Jones, MD Sub-Investigator: Sidney Worsham, MD United States, West Virginia Charleston Area Medical Center Recruiting Charleston, West Virginia, United States, 25301 Contact: James Tierney, DO 304-388-9944 Principal Investigator: James Tierney, DO Sub-Investigator: Samuel Deem, DO Less << | |
NCT00285701 | Colorectal Cancer | Phase 1 Phase 2 | Completed | - | Germany ... More >> Dept of Medicine, Munic-Hospital Pasing Munic, Bayern, Germany Less << |
NCT00708942 | - | Terminated(Slow recruitment, s... More >>tudy stopped with only 13 of 70 patients included in second part of the study) Less << | - | - | |
NCT00052637 | Bladder Cancer | Phase 3 | Completed | - | United States, California ... More >> Jonsson Comprehensive Cancer Center, UCLA Los Angeles, California, United States, 90095 Less << |
NCT02367547 | Neoplasms, Basal Cell ... More >> Carcinoma, Basal Cell Photochemotherapy Photosensitizing Agents Less << | Phase 1 Phase 2 | Recruiting | December 2022 | Finland ... More >> Joint Authority for Päijät-Häme Social and Health Care Recruiting Lahti, Finland, 15850 Less << |
NCT01050309 | Pharmacokinetics | Phase 1 | Completed | - | Netherlands ... More >> Pra-Eds-Nl Zuidlaren, Netherlands, 9471 Less << |
NCT01166230 | - | Completed | - | - | |
NCT01166230 | - | Completed | - | - | |
NCT01344902 | Colon Cancer | Phase 1 Phase 2 | Terminated(The study was stopp... More >>ed due to inadequate efficacy after 13 patients were evaluated.) Less << | - | Germany ... More >> Klinikum München Pasing Munich, Germany, 81241 Less << |
NCT00412971 | Bladder Cancer | Phase 3 | Completed | - | Denmark ... More >> Frederiksberg Hospital Frederiksberg, Denmark, 2000 Odense University Hospital Odense, Denmark Less << |
NCT02012036 | - | Completed | - | Germany ... More >> Caritas-Krankenhaus St. Josef, Klinik fuer Urologie Regensburg, Germany, 93059 Klinikverbund Südwest Sindelfingen, Germany, 71065 Less << | |
NCT00785694 | Bladder Cancer | Phase 4 | Withdrawn(Rejected ethics appr... More >>oval in UK and Holland) Less << | - | France ... More >> GE Healthcare Medical Diagnostics Velizy Cedex, Morane Saulnier, France, 78457 Less << |
NCT00412971 | - | Completed | - | - | |
NCT01551407 | Bladder Cancer | Phase 2 | Terminated(slow inclusion rate... More >>) Less << | - | Germany ... More >> LMU Munich Munich, Germany, D-81377 Less << |
NCT00233402 | Bladder Cancer | Phase 3 | Completed | - | - |
NCT00233402 | - | Completed | - | - | |
NCT01303991 | Intermediate or High-risk Blad... More >>der Cancer Less << | Phase 1 | Completed | - | - |
NCT00634621 | - | Completed | - | - | |
NCT00634621 | - | Completed | - | Spain ... More >> GE Healthcare Madrid, Spain, 28108 Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
3.97mL 0.79mL 0.40mL |
19.86mL 3.97mL 1.99mL |
39.72mL 7.94mL 3.97mL |
|
Dissolving Methods |
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:
in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
|